Background : Inflammatory arthritis (rheumatoid arthritis (RA) or spondyloarthritis (SpA) are painful chronic diseases which impair quality of life and work capacity. Biologics are very effective and widely used therapies. However, they are known to entail risks, particularly of infections. The risk of severe infections is of 5%/patient-year with a maximum during the first six month after the initiation of the first biologic therapy.

Patient education (PE) is recommended for the management of chronic diseases. In the case of biologics, PE aims to help patients to learn specific skills particularly on safety issues, e.g stopping the biologic treatment in case of fever or surgery. Safety skills are assessed by the validated BIOSECURE questionnaire. PE seems efficient for safety skills in a few non-randomized studies. In 2010 a national cross sectional survey on 677 patients showed that the risk of incorrect answers in the BIOSECURE questionnaire was 4 times lower among patients who had benefited from an education by a nurse or other kind of educational process (OR =3,8 IC95% :[1,68-8,8].

Aims and Hypothesis: this trial aims to investigate the effects of a nurse-led self-management education face to face intervention on safety skills of patients with arthritis treated par sub cutaneous biologics. Our hypothesis is that the intervention group will report better skills at the 6 months follow up compared to usual care i.e information by the rheumatologist in current consultation.

Methods : multicentric randomized controlled open trial with blinded assessment of the primary outcome. The intervention group will have a nurse education consultation at M 0 and M3 in addition to the usual care by the rheumatologist. The nurse will assess the patients' health beliefs and educational needs, focusing on safety skills, self-injections and motivation. The control group will have usual care by the rheumatologist.

Background Inflammatory arthritis (rheumatoid arthritis (RA) or spondyloarthritis (SpA) are painful chronic diseases which impair quality of life and work capacity. Biologics are very effective and widely used therapies. However, they are known to entail risks, particularly of infections, such as pulmonary infections, tuberculosis, and a few cases of opportunist infections.. The risk of severe infections is of 5%/patient-year with a maximum during the first six month after the initiation of the first biologic therapy.

Patient education (PE) is recommended for the management of chronic diseases. In the case of biologics, PE aims to help patients to learn specific skills particularly on safety issues, e.g stopping the biologic treatment in case of fever or surgery. Safety skills are assessed by the validated BIOSECURE questionnaire, a 54 item questionnaire assessing patients competences to deal with fever, infections, vaccination, and other daily life situations ie travelling, surgery, pregnancy. PE seems efficient for safety skills in a few non-randomized studies. In 2010 a national cross sectional survey on 677 patients showed that the risk of incorrect answers in the BIOSECURE questionnaire was 4 times lower among patients who had benefited from an education by a nurse or other kind of educational process (OR =3,8 IC95% :[1,68-8,8]. Although PE is recommended, a small rate of patients are proposed PE : in the national survey only 30% patients had had a face to face nurse consultation and for 11% patients the nurse consultation was part of a self-management program.

When a biotherapy is initiated, the initiation period is known to be critical for the patients motivation, particularly for patients treated by sub cutaneous biotherapy.

Aims and Hypothesis: this trial aims to investigate, as a primary outcome, the effects of a nurse-led self-management education face to face intervention on safety skills of patients with arthritis treated par sub cutaneous biologics. Our hypothesis is that the intervention group will report better skills at the 6 months follow up compared to usual care i.e information by the rheumatologist in current consultation. As the treatment initiation period is of importance, this trial will also include, as secondary outcomes, disease activity coping, patient's quality of life, self-efficacy. Our hypothesis is that the nurse intervention will increase motivation with positive effects on disease activity, patient's quality of life and coping, as well as self-efficacy.

Methods : multicentric randomized controlled open trial with blinded assessment of the primary outcome.

The pre selection visit will take place during the medical consultation. The rheumatologist will check the eligibility criteria. Eligible patients will receive written information and will be invited to participate in the RCT. The pre selection visit and the selection visit will possibly be done during the same medical consultation. At the selection visit a M0, the patients will sign the non-opposition form, will be assessed for baseline characteristics and complete the questionnaires. The randomization schedule will be prepared by the biostatistician using a computer-generated random numbers. The randomization will take place after the medical consultation and completion of the baseline assessment, in order to preserve the blinding. After randomization, the participants will be either in the intervention group (IG) or the control group (CG). Patients of the intervention group will be referred to the nurse, the same day or within 2 weeks ( maximum 4 weeks) after inclusion.

Intervention group. The intervention group will benefit from the nurse intervention in addition to usual care : follow up by their rheumatologist in hospital or private care according to usual management of biologics treatment.

Nurse intervention At M0, the nurse face to face intervention will include 1/ assessment of the patients' health beliefs and educational needs towards arthritis and treatment through a semi directive questionnaire to enhance communication 2/ Information about biologics 3/ specific education on safety skills and self-injections 4/ Motivational communication on biologics treatment. At M3, the nurse will communicate on the patient's experience and motivation and will reinforce the safety messages.

The MO and M3 intervention will last approximately 1 hour 30. The actual duration of the consultation will be left to the nurse's appreciation depending on the patient's needs and will be collected.

The nurse intervention has been standardized through physical meeting among the centers leading to the development of a dedicated educational booklet including : the components of the educational diagnosis, assessment of the patients of educational needs, safety messages and motivational messages. The elaboration of the booklet is derived from previous work on the BIOSECURE study, recommendations for PE and previous work on educational needs of arthritis patients.

All the nurses have been trained for patient education and self-management (University 1 year curriculum or minimum 40 hours training) and specifically for safety issues of biologics.

Control group. The control group will be followed up by their rheumatologist in hospital or private care according to usual management of biologics treatment.

Baseline characteristics

Baseline assessment will include demographics features, age, gender, education level, disease duration, type of arthritis ( RA versus SpA), disease activity measured by the DAS 28 (Disease Activity index) for the patients with RA and the BASDAI ( Bath ankylosing spondylitis disease activity index) for the patients with SpA, comorbidities, patients previous self-reported knowledge, quality of life (SF12), coping and psychological well-being (VASs from the RAID score, AHI Arthritis helplessness index), Disease activity (DAS, ASDAS, BASDAI), beliefs about medication ( BMQ)

Final assessment

Patients of both groups (IG and CG) will be assessed at M6 for primary and secondary outcomes. The administration of the questionnaires will be done by a member of the multidisciplinary team blinded for the treatment group. An additional nurse consultation will be proposed independently to the trial to the patients especially those whose safety knowledge will be proved to be inadequate at M6 assessment.

Inclusion Criteria:

• Age 18-75 years
• Patients with RA ( ACR/EULAR criteria), axial or peripheral Spondyloarthritis (ASAS criteria), patients who are eligible for a Sub cutaneous biologic treatment according to the French recommendations of care
• patients naïve from biologics.
• Patients benefiting from French Social Security insurance.

Exclusion Criteria:

• Patients unable to speak or read French language,
• Patients unable to complete a questionnaire or meet with the trial obligations
• Patients suffering from severe cognitive or psychiatric dysfunction